Reasons for discontinuation
“Planned end of therapy only accounts for a small proportion of treatment discontinuations, especially in the relapsed setting,” Dr. Weisel said. “Patients are discontinuing treatment due to reasons other than relapse, ultimately receiving fixed-duration therapy.”
The most common reasons for discontinuation of first-line therapy were:
- Relapse for VCd.
- Planned end of therapy for VRd.
- Adverse events (AEs) for VD and VTd.
- AEs and “other reasons” for Rd.
The most common reasons for discontinuation of second-line therapy were:
- Planned end of therapy for VCd.
- AEs, relapse, and other reasons for VRd.
- Relapse for VD, KRd, and Dara.
- AEs for Rd and IRd.
- AEs and other reasons for Kd.
The most common reasons for discontinuation of third-line therapy were:
- AEs for VCd, Vd, and KRd.
- Relapse for Kd, IRd, and Dara.
- Relapse and other reasons for VRd.
- AEs and other reasons for Rd.
The most common AE leading to discontinuation, across all treatment regimens, was peripheral neuropathy. This suggests peripheral neuropathy is still the “biggest impediment for continuous treatment,” Dr. Weisel said.
INSIGHT MM is sponsored by Takeda. Dr. Weisel reported relationships with Takeda and several other companies.
SOURCE: Weisel K et al. IMW 2019, Abstract OAB-005.